Maze Therapeutics, Inc. (MAZE) stock
MAZENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$32.87−1.03 (-3.04%)
Close on Nov 17, 2026Market cap $1.83BP/E –Yield –
Maze Therapeutics pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
Maze Therapeutics's pe ratio was 12.4× on Jul 31, 2025.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2025 | Jul 31, 2025 | 12.4× | – |
See a number that looks wrong?